Imophoron: against COVID-19 ^Company

Entity: Imophoron

Category: Vaccine Development

Description: Imophoron vision is to provide the world with the next-generation of therapeutics for unmet medical needs and future threats.

Project: ADDomer Rapid-response Platform

Summary: Imophoron stated on its website that preclinical trials of its vaccine candidates will begin “within weeks.” The U.K. startup, based at the Unit DX Incubator in Bristol, said it is looking for partners to further the development of the COVID-19 candidates and the ADDomer rapid-response platform for vaccines to combat present and future infectious diseases. Imophoron cites as advantages of its approach the avoidance of induction of disease-enhancing antibody responses, ready manufacture and thermostability, avoiding the need for cold chain storage.